These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 20536182)
1. Discovery and optimization of boronic acid based inhibitors of autotaxin. Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182 [TBL] [Abstract][Full Text] [Related]
3. Development of an activity-based probe for autotaxin. Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977 [TBL] [Abstract][Full Text] [Related]
5. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Albers HM; Dong A; van Meeteren LA; Egan DA; Sunkara M; van Tilburg EW; Schuurman K; van Tellingen O; Morris AJ; Smyth SS; Moolenaar WH; Ovaa H Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7257-62. PubMed ID: 20360563 [TBL] [Abstract][Full Text] [Related]
6. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666 [TBL] [Abstract][Full Text] [Related]
7. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs. North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587 [TBL] [Abstract][Full Text] [Related]
8. Structure-based design of novel boronic acid-based inhibitors of autotaxin. Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078 [TBL] [Abstract][Full Text] [Related]
9. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution. Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699 [TBL] [Abstract][Full Text] [Related]
10. Optimization of a pipemidic acid autotaxin inhibitor. Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX). East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039 [TBL] [Abstract][Full Text] [Related]
13. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821 [TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship for aryl and heteroaryl boronic acid inhibitors of hormone-sensitive lipase. Ebdrup S; Jacobsen P; Farrington AD; Vedsø P Bioorg Med Chem; 2005 Mar; 13(6):2305-12. PubMed ID: 15727879 [TBL] [Abstract][Full Text] [Related]
15. Regulation and biological activities of the autotaxin-LPA axis. van Meeteren LA; Moolenaar WH Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484 [TBL] [Abstract][Full Text] [Related]
16. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138 [TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050 [TBL] [Abstract][Full Text] [Related]
18. Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Harper K; Arsenault D; Boulay-Jean S; Lauzier A; Lucien F; Dubois CM Cancer Res; 2010 Jun; 70(11):4634-43. PubMed ID: 20484039 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929 [TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidylmethanol is a pan lysophosphatidic acid receptor agonist and is produced by autotaxin in blood. Endo T; Kano K; Motoki R; Hama K; Okudaira S; Ishida M; Ogiso H; Tanaka M; Matsuki N; Taguchi R; Kanai M; Shibasaki M; Arai H; Aoki J J Biochem; 2009 Aug; 146(2):283-93. PubMed ID: 19416959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]